Editorial Comment
Editorial Comment to “Efficacy and safety of dose-dense gemcitabine plus cisplatin as neoadjuvant chemotherapy for muscle-invasive bladder cancer”
-
Efficacy and safety of dose-dense gemcitabine plus cisplatin as neoadjuvant chemotherapy for muscle-invasive bladder cancer
- Yuto Hattori,
- Tasuku Fujiwara,
- Hiroki Hagimoto,
- Hidetoshi Kokubun,
- Shiori Murata,
- Noriyuki Makita,
- Yohei Abe,
- Masashi Kubota,
- Yoichiro Tohi,
- Naofumi Tsutsumi,
- Noboru Shibasaki,
- Koji Inoue,
- Mutsushi Kawakita,
- Toshinari Yamasaki,
- Volume 31Issue 10International Journal of Urology
- pages: 1102-1106
- First Published online: July 3, 2024
Eiji Kikuchi MD, PhD,
Corresponding Author
Eiji Kikuchi MD, PhD
Department of Urology, St. Marianna University School of Medicine, Kawasaki City, Kanagawa, Japan
Search for more papers by this author Nozomi Hayakawa MD, PhD,
Nozomi Hayakawa MD, PhD
Department of Urology, St. Marianna University School of Medicine, Kawasaki City, Kanagawa, Japan
Search for more papers by this author
Eiji Kikuchi MD, PhD,
Corresponding Author
Eiji Kikuchi MD, PhD
Department of Urology, St. Marianna University School of Medicine, Kawasaki City, Kanagawa, Japan
Search for more papers by this author Nozomi Hayakawa MD, PhD,
Nozomi Hayakawa MD, PhD
Department of Urology, St. Marianna University School of Medicine, Kawasaki City, Kanagawa, Japan
Search for more papers by this author
First published: 16 July 2024
No abstract is available for this article.
CONFLICT OF INTEREST STATEMENT
Eiji Kikuchi is an Editorial Board member of the International Journal of Urology and a co-author of this article. To minimize bias, he was excluded from all editorial decision-making related to the acceptance of this article for publication. Eiji Kikuchi received honoraria for lectures from MSD K.K. Nippon Kayaku and Astellas Pharma, Inc.
REFERENCES
- 1Hattori Y, Fujiwara T, Hagimoto H, Kokubun H, Murata S, Makita N, et al. Efficacy and safety of dose-dense gemcitabine plus cisplatin as neoadjuvant chemotherapy for muscle-invasive bladder cancer. Int J Urol. 2024; 31: 1102–1107.
- 2 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Bladder Cancer Version 4.2024—May 9, 2024. https://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf
- 3Pfister C, Gravis G, Flechon A, Soulié M, Guy L, Laguerre B, et al. Randomized phase III trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin, or gemcitabine and cisplatin as perioperative chemotherapy for patients with muscle-invasive bladder cancer. Analysis of the GETUG/AFU V05 VESPER trial secondary endpoints: chemotherapy toxicity and pathological responses. Eur Urol. 2021; 79: 214–221.
- 4Kitamura H, Tsukamoto T, Shibata T, Masumori N, Fujimoto H, Hirao Y, et al. Randomised phase III study of neoadjuvant chemotherapy with methotrexate, doxorubicin, vinblastine and cisplatin followed by radical cystectomy compared with radical cystectomy alone for muscle-invasive bladder cancer: Japan clinical oncology group study JCOG0209. Ann Oncol. 2014; 25: 1192–1198.
